How Beacon Behavioral Partners Uses Platform Scale to Unlock Interventional Care
By Laura Lovett
October 6, 2026
Share:
Join leading names in behavioral health—including Rob Jardeleza, CEO of Beacon Behavioral Partners—at INVEST in Phoenix, Arizona, Oct. 28–30. Dozens of providers and more than eight investors will be presenting. Don’t miss the chance to connect with industry leaders. Register here.
Beacon Behavioral Partners has been one of the most active buyers in the mental health market over the past few years. The Lattice Capital-backed business has grown to more than 70 locations across 35 partnerships. Its model is focused on purchasing psychiatrist-owned businesses, providing back-end support, while giving clinicians an ownership stake in the company, allowing them to stay focused on the clinical side of the business.
As the company looks to the future, it sees interventional psychiatry as a key area for growth. This subspecialty uses devices and substances to target brain circuits involved in severe or treatment-resistant mental health conditions.
"We are moving into an age … where we can move from treatment to healing," Rob Jardeleza, CEO of Beacon Behavioral Partners, recently told Behavioral Health Business in a webinar. "So, for our treatment-resistant depression patients today, there are two modalities: there’s TMS and there is Spravato, and they are both very effective."
Jardeleza, who previously worked in the physical health sector, compared the field’s evolution to advancements in cardiology. He noted that a patient undergoing a diagnostic left heart catheterization once would have required an inpatient stay. Advancements have since shifted that care to an outpatient setting.
Additional interventional psychiatry tools could also reach the market. He noted that psilocybin is expected to receive FDA approval in 2027, and an LSD derivative could follow in 2028 to treat anxiety and other conditions.
As the operator grows its service lines and footprint, securing payer coverage remains a key consideration for interventional psychiatry.